. Author manuscript; available in PMC: 2023 Jun 1.

Published in final edited form as: Hematol Oncol Clin North Am. 2022 May 11;36(3):553–567. doi: 10.1016/j.hoc.2022.02.007

Table 1:

Select studies evaluating the role of local therapy for colorectal liver metastases

Author	Treatment modality	Study design	Number of patients	Lesion size	Local control or complete response rate	Acute mild/grade 1–2 toxicities	Acute severe/grade 3+ toxicities
Choti et al⁵⁴	Surgery	Retrospective	226	Median 3.9 cm	5-yr disease-free survival 20%	NR	2 peri-operative deaths
Petrelli et al⁵⁵	SABR	Systematic review	656	Median 2–3.5 cm (0.6 – 11.6)	60 – 96%	31%	9%
Van Amerongen et al⁵⁶	RFA vs surgical resection	Meta-analysis	751 RFA 1,276 surgery	NR	32–82% RFA 77–98% surgery	Total complication rate reported: 12% RFA, 2 grade 5 25% surgery, 8 grade 5
Kron et al⁵⁷	RFA vs surgical resection	Systematic review	779 RFA 1359 surgery	NR	24–85% RFA 60–98 % surgery	NR	NR
Gavriildis et al⁵⁸	MWA vs RFA vs surgery	Meta-analysis	350 MWA 1253 RFA 1798 Surgery	NR	42–74% MWA 63–71% RFA 43–94% Surgery	NR	NR
Correa-Gallego et al⁵⁹	Open RFA or MWA	Retrospective	127	Median 1.0 cm (1.0–2.0)	80% for RFA at 2.5 years, 94% for MWA at 18 months	24% vs 27%	Not reported
Wasan et al¹⁰	FOLFOX +/− TARE	Combined analysis of 3 phase III trials	1,103	NR	At best response, CR rate 4.5% for TARE+FOLFOX vs 1.6% for FOLFOX alone	74% TARE+FOLFOX 67% FOLFOX alone	16.4% from TARE, 8 were grade 5
Van Hazel et al⁶⁰	TARE + FOLFOX vs FOLFOX + Bevacizumab	Phase III randomized trial	263 mFOLFOX6 267 TARE + mFOLFOX6	NR	At best response, CR rate 6% mFOLFOX6 + TARE 1.9% mFOLFOX6	58% with TARE + mFOLFOX6 46% with mFOLFOX6 + Bevacizumab	85.4% with TARE, 9 were grade 5 73% with FOLFOX + Bev, 5 were grade 5
Kemeny et Al¹⁷	5-FU +/− HAI	Phase III randomized trial	74 5-FU/leucovorin 82 5-FU/leucovorin + HAI	NR	2-yr survival free of hepatic recurrence 60% 5-FU/leucovorin 90% 5-FU/leucovorin + HAI	NR	7% 5-FU/leucovorin 6% 5-FU/leucovorin + HAI

Abbreviations: CR, complete response; HAI, hepatic artery infusion; MWA, microwave ablation; NR, not reported; OS, overall survival; RFA, radiofrequency ablation; SABR, stereotactic ablative radiotherapy; TARE, transarterial radioembolization